{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=BYL-719+%28alpelisib%29&page=2", "query": { "intervention": "BYL-719 (alpelisib)", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 77, "total_pages": 8, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=BYL-719+%28alpelisib%29&page=3&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=BYL-719+%28alpelisib%29&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-06T11:38:23.354Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT04965688", "title": "Biology Guided Therapy for Breast Cancer for ER Positive", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Breast Cancer", "Estrogen Receptor-positive Breast Cancer", "HER2-negative Breast Cancer" ], "interventions": [ { "name": "Biopsy-Guided Therapy Selection", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Inova Health Care Services", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 2, "start_date": "2021-08-08", "completion_date": "2024-03-13", "has_results": true, "last_update_posted_date": "2025-04-10", "last_synced_at": "2026-10-06T11:38:23.354Z", "location_count": 1, "location_summary": "Fairfax, Virginia", "locations": [ { "city": "Fairfax", "state": "Virginia" } ], "official_url": "https://clinicaltrials.gov/study/NCT04965688" }, { "nct_id": "NCT01719380", "title": "Study of LGX818 and Cetuximab or LGX818, BYL719, and Cetuximab in BRAF Mutant Metastatic Colorectal Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Colorectal Cancer" ], "interventions": [ { "name": "LGX818", "type": "DRUG" }, { "name": "Cetuximab", "type": "DRUG" }, { "name": "BYL719", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 156, "start_date": "2012-11-23", "completion_date": "2019-02-12", "has_results": true, "last_update_posted_date": "2021-06-23", "last_synced_at": "2026-10-06T11:38:23.354Z", "location_count": 32, "location_summary": "Los Angeles, California • Santa Monica, California • New Haven, Connecticut + 14 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01719380" }, { "nct_id": "NCT04729387", "title": "Alpelisib Plus Olaparib in Platinum-resistant/Refractory, High-grade Serous Ovarian Cancer, With no Germline BRCA Mutation Detected", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Ovarian Cancer" ], "interventions": [ { "name": "Alpelisib", "type": "DRUG" }, { "name": "Olaparib", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Pegylated liposomal doxorubicin (PLD)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "100 Years", "sex": "ALL", "summary": "18 Years to 100 Years" }, "enrollment_count": 358, "start_date": "2021-07-22", "completion_date": "2026-01-19", "has_results": true, "last_update_posted_date": "2026-06-04", "last_synced_at": "2026-10-06T11:38:23.354Z", "location_count": 16, "location_summary": "Phoenix, Arizona • Fort Myers, Florida • West Palm Beach, Florida + 10 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Fort Myers", "state": "Florida" }, { "city": "West Palm Beach", "state": "Florida" }, { "city": "Silver Spring", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT04729387" }, { "nct_id": "NCT05948943", "title": "Alpelisib in Pediatric and Adult Patients With Lymphatic Malformations Associated With a PIK3CA Mutation.", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "Lymphatic Malformations" ], "interventions": [ { "name": "Alpelisib", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "0 Years", "maximum_age": "100 Years", "sex": "ALL", "summary": "0 Years to 100 Years" }, "enrollment_count": 232, "start_date": "2023-11-24", "completion_date": "2033-05-02", "has_results": false, "last_update_posted_date": "2026-09-18", "last_synced_at": "2026-10-06T11:38:23.354Z", "location_count": 18, "location_summary": "Oakland, California • Orange, California • Palo Alto, California + 13 more", "locations": [ { "city": "Oakland", "state": "California" }, { "city": "Orange", "state": "California" }, { "city": "Palo Alto", "state": "California" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Jacksonville", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT05948943" }, { "nct_id": "NCT07543822", "title": "24VA022; VATCH Alpelisib for TIE2/PIK3CA Pathway VAs", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Vascular Anomalies", "Vascular Anomaly", "TIE2/PIK3CA Pathway Driven Vascular Anomalies" ], "interventions": [ { "name": "alpelisib (BYL719)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Children's Hospital of Philadelphia", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "2 Years", "maximum_age": "30 Years", "sex": "ALL", "summary": "2 Years to 30 Years" }, "enrollment_count": 61, "start_date": "2025-08-27", "completion_date": "2030-08-27", "has_results": false, "last_update_posted_date": "2026-04-22", "last_synced_at": "2026-10-06T11:38:23.354Z", "location_count": 1, "location_summary": "Philadelphia, Pennsylvania", "locations": [ { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT07543822" }, { "nct_id": "NCT01219699", "title": "A Study of BYL719 in Adult Patients With Advanced Solid Malignancies, Whose Tumors Have an Alteration of the PIK3CA Gene", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Solid Tumors With an Alteration of the PIK3CA Gene", "Estrogen Receptor Positive Breast Cancer" ], "interventions": [ { "name": "BYL719", "type": "DRUG" }, { "name": "Fulvestrant", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 221, "start_date": "2010-10-05", "completion_date": "2020-04-16", "has_results": false, "last_update_posted_date": "2020-09-22", "last_synced_at": "2026-10-06T11:38:23.354Z", "location_count": 5, "location_summary": "San Francisco, California • Boston, Massachusetts • Nashville, Tennessee + 1 more", "locations": [ { "city": "San Francisco", "state": "California" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Nashville", "state": "Tennessee" }, { "city": "Nashville", "state": "Tennessee" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01219699" }, { "nct_id": "NCT04980833", "title": "Study Assessing Long-term Safety and Efficacy of Alpelisib in Patients With PIK3CA-Related Overgrowth Spectrum (PROS) Who Previously Participated in Study CBYL719F12002 (EPIK-P1)", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "PIK3CA-related Overgrowth Spectrum (PROS)" ], "interventions": [ { "name": "Alpelisib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "2 Years", "maximum_age": "100 Years", "sex": "ALL", "summary": "2 Years to 100 Years" }, "enrollment_count": 41, "start_date": "2022-01-27", "completion_date": "2027-08-20", "has_results": false, "last_update_posted_date": "2026-04-02", "last_synced_at": "2026-10-06T11:38:23.354Z", "location_count": 1, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT04980833" }, { "nct_id": "NCT02282371", "title": "Cetuximab + BYL719 + IMRT (Intensity-Modulated Radiation Therapy) in Stage III/IVB Head and Neck Squamous Cell Cancer (HNSCC)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Head and Neck Squamous Cell Cancer" ], "interventions": [ { "name": "Cetuximab", "type": "DRUG" }, { "name": "BYL719", "type": "DRUG" }, { "name": "IMRT (Intensity-Modulated Radiation Therapy)", "type": "RADIATION" } ], "intervention_types": [ "DRUG", "RADIATION" ], "sponsor": "Memorial Sloan Kettering Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 16, "start_date": "2014-10-30", "completion_date": "2021-10-22", "has_results": false, "last_update_posted_date": "2021-10-26", "last_synced_at": "2026-10-06T11:38:23.354Z", "location_count": 6, "location_summary": "Basking Ridge, New Jersey • Middletown, New Jersey • Commack, New York + 3 more", "locations": [ { "city": "Basking Ridge", "state": "New Jersey" }, { "city": "Middletown", "state": "New Jersey" }, { "city": "Commack", "state": "New York" }, { "city": "Harrison", "state": "New York" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT02282371" }, { "nct_id": "NCT05090358", "title": "Preventing High Blood Sugar in People Being Treated for Metastatic Breast Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Breast Cancer", "Breast Cancer Stage IV", "Metastatic Breast Cancer" ], "interventions": [ { "name": "Ketogenic Diet", "type": "DIETARY_SUPPLEMENT" }, { "name": "Low Carbohydrate Diet", "type": "DIETARY_SUPPLEMENT" }, { "name": "Alpelisib", "type": "DRUG" }, { "name": "Fulvestrant", "type": "DRUG" }, { "name": "Canagliflozin", "type": "DRUG" } ], "intervention_types": [ "DIETARY_SUPPLEMENT", "DRUG" ], "sponsor": "Memorial Sloan Kettering Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 15, "start_date": "2021-10-08", "completion_date": "2027-10-08", "has_results": false, "last_update_posted_date": "2026-08-11", "last_synced_at": "2026-10-06T11:38:23.354Z", "location_count": 9, "location_summary": "Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 5 more", "locations": [ { "city": "Basking Ridge", "state": "New Jersey" }, { "city": "Middletown", "state": "New Jersey" }, { "city": "Montvale", "state": "New Jersey" }, { "city": "Commack", "state": "New York" }, { "city": "East White Plains", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT05090358" }, { "nct_id": "NCT05933395", "title": "Genetically-informed Therapy for ER+ Breast Cancer Post-CDK4/6 Inhibitor", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Advanced Breast Cancer" ], "interventions": [ { "name": "Fulvestrant", "type": "DRUG" }, { "name": "Neratinib", "type": "DRUG" }, { "name": "Alpelisib", "type": "DRUG" }, { "name": "Everolimus", "type": "DRUG" }, { "name": "Abemaciclib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Dartmouth-Hitchcock Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 135, "start_date": "2024-09-23", "completion_date": "2031-10", "has_results": false, "last_update_posted_date": "2026-01-20", "last_synced_at": "2026-10-06T11:38:23.354Z", "location_count": 1, "location_summary": "Lebanon, New Hampshire", "locations": [ { "city": "Lebanon", "state": "New Hampshire" } ], "official_url": "https://clinicaltrials.gov/study/NCT05933395" } ] }